Pulmonary Tuberculosis and delay in anti-tuberculous treatment are important risk factors for chronic obstructive pulmonary disease

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Lee, Chih Hsin ^a,b,c   Lee, Ming Chia ^b   Lin, Hsien Ho ^a   Shu, Chin Chung ^d   Wang, Jann Yuan ^d   Lee, Li Na ^d   Chao, Kun Mao ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^c TZU CHI UNIVERSITY   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

TUBERCULOSTATIC AGENT;

ADULT; AGE; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DATA BASE; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; GENDER; HUMAN; LOWEST INCOME GROUP; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; NATIONAL HEALTH INSURANCE; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT PARTICIPATION; RISK ASSESSMENT; RISK FACTOR; TAIWAN; THERAPY DELAY; TUBERCULOSIS;

ADULT; AGE OF ONSET; AGED; ANTITUBERCULAR AGENTS; COHORT STUDIES; EARLY MEDICAL INTERVENTION; FEMALE; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS; TUBERCULOSIS, PULMONARY;

EID: 84861475738     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0037978     Document Type: Article

References (29)

1. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, et al. (2007) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 176: 532-555.
2. Theakston F, (2008) World Health Statistics. WHO press Geneva, World Health Organization.
3. Lopez AD, Shibuya K, Rao C, Mathers CD, Hansell AL, et al. (2006) Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J 27: 397-412.
4. Salvi SS, Barnes PJ, (2009) Chronic obstructive pulmonary disease in non-smokers. Lancet 374: 733-743.
5. Behrendt CE, (2005) Mild and moderate-to-severe COPD in nonsmokers: distinct demographic profiles. Chest 128: 1239-1244.
6. Ehrlich RI, White N, Norman R, Laubscher R, Steyn K, et al. (2004) Predictors of chronic bronchitis in South African adults. Int J Tuberc Lung Dis 8: 369-376.
7. Blanc L, Falzon D, Fitzpatrick C, Floyd K, Garcia I, et al. (2010) Global tuberculosis control 2010. Geneva, Switzerland World Health Organization.
8. Grzybowski S, (1987) Cost in tuberculosis control. Tubercle 68: 33-37.
9. Frieden TR, Sbarbaro JA, (2007) Promoting adherence to treatment for tuberculosis: the importance of direct observation. Bull World Health Organ 85: 407-409.
10. Snider GL, Doctor L, Demas TA, Shaw AR, (1971) Obstructive airway disease in patients with treated pulmonary tuberculosis. Am Rev Respir Dis 103: 625-640.
11. Hnizdo E, Singh T, Churchyard G, (2000) Chronic pulmonary function impairment caused by initial and recurrent pulmonary tuberculosis following treatment. Thorax 55: 32-38.
12. Chung KP, Chen JY, Lee CH, Wu HD, Wang JY, et al. (2011) Trends and predictors of changes in pulmonary function after treatment for pulmonary tuberculosis. Clinics (Sao Paulo) 66: 549-556.
13. Pasipanodya JG, Miller TL, Vecino M, Munguia G, Garmon R, et al. (2007) Pulmonary impairment after tuberculosis. Chest 131: 1817-1824.
14. Luh K-T, eds. (2011) Taiwan Guidelines for TB Diagnosis and Treatment. 4th ed. Taipei, Taiwan Centers for Disease Control, R.O.C. (Taiwan).
15. Steen TW, Mazonde GN, (1998) Pulmonary tuberculosis in Kweneng District, Botswana: delays in diagnosis in 212 smear-positive patients. Int J Tuberc Lung Dis 2: 627-634.
16. Lawn SD, Afful B, Acheampong JW, (1998) Pulmonary tuberculosis: diagnostic delay in Ghanaian adults. Int J Tuberc Lung Dis 2: 635-640.
17. Lin HH, Ezzati M, Chang HY, Murray M, (2009) Association between tobacco smoking and active tuberculosis in Taiwan: prospective cohort study. Am J Respir Crit Care Med 180: 475-480.
18. Elkington P, Shiomi T, Breen R, Nuttall RK, Ugarte-Gil CA, et al. (2011) MMP-1 drives immuno-pathology in human tuberculosis and transgenic mice. J Clin Invest 121: 1827-1833.
19. Caballero A, Torres-Duque CA, Jaramillo C, Bolivar F, Sanabria F, et al. (2008) Prevalence of COPD in five Colombian cities situated at low, medium, and high altitude (PREPOCOL study). Chest 133: 343-349.
20. Long R, Maycher B, Dhar A, Manfreda J, Hershfield E, et al. (1998) Pulmonary tuberculosis treated with directly observed therapy: serial changes in lung structure and function. Chest 113: 933-943.
21. Pirkis JE, Speed BR, Yung AP, Dunt DR, MacIntyre CR, et al. (1996) Time to initiation of anti-tuberculosis treatment. Tuber Lung Dis 77: 401-406.
22. Garrigo M, Aragon LM, Alcaide F, Borrell S, Cardenosa E, et al. (2007) Multi-center laboratory evaluation of the MB/BacT Mycobacterium detection system and the BACTEC MGIT 960 system in comparison with the BACTEC 460TB system for susceptibility testing of Mycobacterium tuberculosis. J Clin Microbiol 45: 1766-1770.
23. Shang S, Ordway D, Henao-Tamayo M, Bai X, Oberley-Deegan R, et al. (2011) Cigarette smoke increases susceptibility to tuberculosis-evidence from in vivo and in vitro models. J Infect Dis 203: 1240-1248.
24. (2003) COPD prevalence in 12 Asia-Pacific countries and regions: projections based on the COPD prevalence estimation model. Respirology 8: 192-198.
25. Lee SW, Kim YS, Kim DS, Oh YM, Lee SD, (2011) The risk of obstructive lung disease by previous pulmonary tuberculosis in a country with intermediate burden of tuberculosis. J Korean Med Sci 26: 268-273.
26. Elkington PT, Ugarte-Gil CA, Friedland JS, (2011) Matrix metalloproteinases in tuberculosis. Eur Respir J 38: 456-464.
27. Omachi TA, Eisner MD, Rames A, Markovtsova L, Blanc PD, (2011) Matrix metalloproteinase-9 predicts pulmonary status declines in alpha1-antitrypsin deficiency. Respir Res 12: 35.
28. Chanchamroen S, Kewcharoenwong C, Susaengrat W, Ato M, Lertmemongkolchai G, (2009) Human polymorphonuclear neutrophil responses to Burkholderia pseudomallei in healthy and diabetic subjects. Infect Immun 77: 456-463.
29. Geerlings SE, Hoepelman AI, (1999) Immune dysfunction in patients with diabetes mellitus (DM). FEMS Immunol Med Microbiol 26: 259-265.